Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Samsung Biologics has disclosed the details of its listing change scheduled for November 24, 2025, following a corporate spin-off, along with the lifting of trading suspension on the same date.
📊 [Key Disclosure Details & Financial Figures]
- Listed Class: Samsung Biologics Common Stock
- Number and Type of Shares:
- Before Change: 71,174,000 registered common shares
- After Change: 46,290,951 registered common shares
- Net Change in Shares: -24,883,049 shares
- Par Value per Share: KRW 2,500
- Issue Date: November 3, 2025 (4th Issue)
- Dividend Accrual Date: January 1, 2025
- Fiscal Year-End: End of December
- Listing Change Date: November 24, 2025
- Reason for Listing Change: Corporate spin-off (surviving entity)
- Trading Suspension Lift Date: Listing change date (November 24, 2025)
- Stock Identification Codes: Standard Code KR7207940008 / Ticker Symbol A207940
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Verifying the Execution of Listing Change and Trading Suspension Lift on November 24, 2025
This disclosure provides notice regarding the schedule for the company’s listing change on the KOSPI market, under which total common shares will be adjusted from 71,174,000 to 46,290,951 following the spin-off.
Checking whether the listing change process proceeds as scheduled on November 24, 2025, and verifying that trading suspension is officially lifted on that date is essential.
Relevant details can be verified in Korea Exchange (KRX) market announcements and official disclosures on November 24, 2025.
📢 Disclaimer & Source Notice
Source: This content was structured and regenerated based on official data submitted to the Financial Supervisory Service’s DART system.
Investment Risk Warning: This content is provided solely for informational and educational purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any security. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
